Posted inNews and Updates
Why Clinical AI Fails: The Path to Reliable Medical Tech
Clinical AI often hits a performance wall in real-world hospitals. Discover the core challenges of data bias and integration, and how to fix them for success.
Posted inNews and Updates
AI-Designed Parkinson’s Drug Enters First Human Trial
In a milestone for medicine, a drug designed by AI has entered human trials. Discover how this innovative approach could change Parkinson's treatment.
Posted inNews and Updates
UniQure Plans New FDA Bid for Huntington’s Gene Therapy
UniQure is set to re-engage the FDA for its Huntington’s disease gene therapy, aiming to overcome previous regulatory hurdles with new clinical data.
Posted inNews and Updates
uniQure Sets Regulatory Path for AMT-130 Huntington’s Therapy
uniQure eyes FDA approval for AMT-130, a breakthrough gene therapy for Huntington’s disease. Learn the latest on this potential genetic treatment.
Posted inNews and Updates
First Human Receives Wireless Brain-Computer Interface
A major medical milestone as the first human receives a wireless Paradromics BCI, designed to restore communication for those with speech impairments.
Posted inNews and Updates
New Liver-Targeted Insulin: A Breakthrough for Type 1 Diabetes
A new liver-targeted insulin shows potential to improve Type 1 Diabetes management by reducing hypoglycemia risks. Discover how this therapy mimics nature.
Posted inNews and Updates
VahatiCor Launches First U.S. Trial for CMD Heart Device
VahatiCor has enrolled the first U.S. patient in the SERRA-I trial, testing the A-FLUX Reducer System® to treat Coronary Microvascular Dysfunction (CMD).
Posted inNews and Updates
Latin Clinical Trial Center Partners to Boost Puerto Rico Research
Latin Clinical Trial Center and PhaseWell Research partner to scale clinical trials in Puerto Rico, enhancing patient access to innovative new therapies.
Posted inNews and Updates
Nanvuranlat Phase 3 Trials Advance After FDA Alignment
Nanvuranlat enters Phase 3 clinical trials following FDA alignment. Learn about the latest developments in this promising oncology therapeutic candidate.
Posted inNews and Updates
Edgewise Therapeutics Reports Positive CIRRUS-HCM Results
Edgewise Therapeutics announces positive Phase II results for EDG-7500 in treating hypertrophic cardiomyopathy. See how this breakthrough impacts heart care.